Cornerstone Wealth Management LLC lowered its stake in shares of Eli Lilly and Co (NYSE:LLY) by 28.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,766 shares of the company’s stock after selling 1,082 shares during the quarter. Cornerstone Wealth Management LLC’s holdings in Eli Lilly and were worth $238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Janus Henderson Group PLC increased its position in shares of Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the period. Dodge & Cox increased its position in shares of Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. Renaissance Technologies LLC increased its position in shares of Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the period. Bank of Montreal Can increased its position in shares of Eli Lilly and by 85.4% during the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock valued at $391,156,000 after buying an additional 2,133,606 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the period. Institutional investors own 75.71% of the company’s stock.
Several equities analysts recently issued reports on LLY shares. Morgan Stanley boosted their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 21st. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Wednesday, November 1st. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Finally, Bank of America cut their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and has a consensus rating of “Hold” and an average price target of $93.22.
In other news, insider Donald A. Zakrowski sold 876 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total value of $67,933.80. Following the transaction, the insider now owns 4,130 shares in the company, valued at $320,281.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 260,486 shares of company stock worth $22,795,340. Insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE LLY) opened at $78.75 on Friday. The firm has a market cap of $84,569.20, a PE ratio of -393.73, a price-to-earnings-growth ratio of 1.44 and a beta of 0.23. The company has a quick ratio of 1.03, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.95 earnings per share. equities analysts expect that Eli Lilly and Co will post 4.87 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently -1,124.94%.
COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Co (LLY) Shares Sold by Cornerstone Wealth Management LLC” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://transcriptdaily.com/2018/02/24/eli-lilly-and-co-lly-shares-sold-by-cornerstone-wealth-management-llc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.